## Clinical Staging and Risk Stratification This patient has **stage IA follicular lymphoma** (single lymph node, no systemic involvement, normal LDH, no B symptoms). This is a low-grade, indolent NHL with an excellent prognosis. ## The "Watch and Wait" Paradigm **Key Point:** Early-stage, asymptomatic, low-grade NHL (especially follicular lymphoma) does NOT require immediate treatment. Observation with surveillance is the standard of care and does not compromise long-term outcomes. **High-Yield:** The "watch and wait" or "observation" strategy is supported by multiple randomized trials (e.g., GELA, PRIMA-HL) showing that: - Delaying treatment in asymptomatic patients does not worsen overall survival - Treatment can be deferred until disease progression (new lymphadenopathy, B symptoms, cytopenias, rising LDH) - Patients benefit from a treatment-free interval and avoid early chemotoxicity ## Surveillance Protocol | Interval | Assessment | | --- | --- | | Every 3 months (first 2 years) | Clinical exam, CBC, LDH | | Every 6 months (years 2–5) | Clinical exam, CBC, LDH | | Annually (after year 5) | Clinical exam, CBC, LDH | | As needed | Imaging (CT/PET) if symptoms or lab abnormalities develop | **Clinical Pearl:** Follicular lymphoma is incurable with current standard therapy, but median overall survival exceeds 15–20 years. Early treatment does not prolong survival and exposes patients to unnecessary toxicity. ## Why Not Treat Now? - **Rituximab monotherapy** (option 1) may be considered for symptomatic or progressive disease, not asymptomatic stage I disease. - **R-CHOP** (option 2) is reserved for symptomatic, progressive, or high-grade disease; it is overtreatment for asymptomatic stage IA follicular lymphoma. - **Radiation therapy** (option 3) is rarely used in modern NHL management and is not indicated for asymptomatic stage I disease. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.